In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akebia Therapeutics Inc.

www.akebia.com

Latest From Akebia Therapeutics Inc.

Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna

Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.

Financing Business Strategies

Astellas Beats Rivals To Japan HIF-PHI Market As Roxadustat Launched

Astellas becomes first to market in Japan in new class of oral anemia drugs, beating multiple rivals in a sector set to see strong growth but also fierce competition.

Japan Launches

Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

Clinical Trials Research & Development

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Gastrointestinal
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akebia Therapeutics Inc.
  • Senior Management
  • John P Butler, Pres. & CEO
    Jason A Amello, SVP, CFO
    Michel Dahan, SVP, CBO
    Rita Jain, MD, SVP, CMO
  • Contact Info
  • Akebia Therapeutics Inc.
    Phone: (617) 871-2098
    245 First St.
    Ste. 1100
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register